FDA Science Board To Discuss Pre- And Postmarketing Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
The scientific advisory panel will discuss the agency's pre- and postmarketing safety programs for drugs and biologics at an April 15 meeting. The group will also discuss good manufacturing practices for vaccines; blood; and cell, tissue and gene products.